PFA Pension Forsikringsaktieselskab Makes New $76.83 Million Investment in Pfizer Inc. $PFE

Key Points

• PFA Pension Forsikringsaktieselskab bought a new stake of 3,074,543 Pfizer shares in Q4 valued at approximately $76.83 million, representing about 0.05% of the company.
• Other major institutions like Vanguard, State Street and Northern Trust also increased positions, leaving hedge funds and institutions owning roughly 68.36% of Pfizer.
• Recent company catalysts include an FDA approval for a Pfizer–Arvinas breast cancer therapy, patent settlements extending Vyndamax exclusivity to 2031 and a late-stage win for Elrexfio, while Pfizer pays a quarterly dividend yielding about 6.5% (ex-dividend May 8) ahead of upcoming Q1 earnings.

PFA Pension Forsikringsaktieselskab purchased a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 3,074,543 shares of the biopharmaceutical company's stock, valued at approximately $76,833,000. PFA Pension Forsikringsaktieselskab owned 0.05% of Pfizer at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Pfizer by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company's stock valued at $13,479,520,000 after buying an additional 7,031,162 shares during the period. State Street Corp increased its stake in shares of Pfizer by 0.9% during the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company's stock valued at $7,620,747,000 after buying an additional 2,786,098 shares during the period. Northern Trust Corp increased its stake in shares of Pfizer by 1.4% during the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company's stock valued at $1,631,225,000 after buying an additional 869,175 shares during the period. Fisher Asset Management LLC increased its stake in shares of Pfizer by 1.9% during the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company's stock valued at $1,255,860,000 after buying an additional 897,786 shares during the period. Finally, Legal & General Group Plc increased its stake in shares of Pfizer by 8.6% during the third quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company's stock valued at $1,063,565,000 after buying an additional 3,296,415 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA approval for a Pfizer–Arvinas breast cancer therapy — The U.S. FDA approved the co‑developed drug for a breast cancer indication, giving Pfizer an additional commercial launch and validating its oncology partnership pipeline. This approval creates a new near‑ and medium‑term revenue opportunity and reduces development risk for the asset. US FDA approves Pfizer, Arvinas' breast cancer drug
• Positive Sentiment: Vyndamax patent settlements extend exclusivity to 2031 — Pfizer reached settlements with multiple generic filers that effectively push back generic entry for Vyndamax (tafamidis), protecting a meaningful revenue stream and reducing downside risk from near‑term generic competition. That supports cash flow visibility into the next decade. Pfizer Reaches Settlement to Extend VYNDAMAX Patent Protection Until 2031
• Positive Sentiment: Late‑stage win for multiple myeloma drug Elrexfio — Pfizer reported a late‑stage trial success for Elrexfio, which could expand its oncology franchise and add future revenue streams if regulatory filings follow. Clinical wins can meaningfully re‑rate biotech exposure over time. Pfizer posts late-stage trial win for multiple myeloma therapy Elrexfio
• Positive Sentiment: PADCEV supplemental BLA accepted for priority review — Pfizer (with Astellas) secured FDA acceptance of a PADCEV sBLA for a new use, which could expand indications and sales if approved. This is another program that supports medium‑term growth optionality. Pfizer Among Best Medical Stocks Under $30 to Invest In?
• Neutral Sentiment: Q1 earnings and guidance in focus (May 5) — Wall Street is watching first‑quarter results and guidance; Zacks and other outlets highlight consensus estimates and key revenue/margin line items, with traders positioning ahead of potential beats and for commentary on obesity and specialty drug performance. Earnings will likely be the short‑term catalyst for direction. Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings
• Negative Sentiment: Analyst caution and price‑target cuts are weighing on sentiment — Goldman reportedly trimmed its target and some sell‑side commentary highlights growth concerns despite the patent wins; Morgan Stanley reiterated Equal Weight and flagged patent/growth uncertainty. That cautious analyst tone can sap momentum and contribute to intraday selling. Pfizer Stock Opinions on Vyndamax Settlements and Earnings Outlook Morgan Stanley Maintains Pfizer at Equal Weight

Pfizer Price Performance

PFE opened at $26.35 on Friday. The business's 50-day moving average is $27.17 and its two-hundred day moving average is $26.09. Pfizer Inc. has a 1 year low of $21.97 and a 1 year high of $28.75. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The firm has a market capitalization of $149.80 billion, a PE ratio of 19.37 and a beta of 0.35.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same quarter in the previous year, the firm earned $0.63 earnings per share. The firm's quarterly revenue was down 1.2% compared to the same quarter last year. Research analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.5%. The ex-dividend date is Friday, May 8th. Pfizer's payout ratio is 126.47%.

Analyst Ratings Changes

Several brokerages have recently commented on PFE. Guggenheim raised their price target on Pfizer from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Tuesday, March 24th. Weiss Ratings restated a "hold (c-)" rating on shares of Pfizer in a research note on Thursday, January 22nd. Zacks Research upgraded Pfizer from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 24th. UBS Group raised their price target on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Monday, April 13th. Finally, Bank of America cut their price target on Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research note on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat, Pfizer has an average rating of "Hold" and an average target price of $28.74.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.